Literature DB >> 30047548

Golimumab for ulcerative colitis: adding perspective to the pursuit.

Jimmy K Limdi1,2.   

Abstract

Entities:  

Keywords:  IBD clinical; inflammatory bowel disease; ulcerative colitis

Year:  2017        PMID： 30047548      PMCID： PMC6056078          DOI： 10.1136/flgastro-2017-100929

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN： 2041-4137


× No keyword cloud information.
  10 in total

1.  Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis.

Authors:  Antonio Tursi; Leonardo Allegretta; Nicola Della Valle; Yusef Hadad; Antonio Penna; Giuseppe Pranzo; Cristina Ricciardelli; Primaldo Paiano; Marcello Picchio
Journal:  Clin Res Hepatol Gastroenterol       Date:  2016-06-11       Impact factor: 2.947

2.  Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.

Authors:  Kristian Thorlund; Eric Druyts; Kabirraaj Toor; Edward J Mills
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-03-12       Impact factor: 3.869

3.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Brian G Feagan; Colleen Marano; Hongyan Zhang; Richard Strauss; Jewel Johanns; Omoniyi J Adedokun; Cynthia Guzzo; Jean-Frederic Colombel; Walter Reinisch; Peter R Gibson; Judith Collins; Gunnar Järnerot; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2013-06-14       Impact factor: 22.682

4.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Brian G Feagan; Colleen Marano; Hongyan Zhang; Richard Strauss; Jewel Johanns; Omoniyi J Adedokun; Cynthia Guzzo; Jean-Frederic Colombel; Walter Reinisch; Peter R Gibson; Judith Collins; Gunnar Järnerot; Toshifumi Hibi; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2013-06-02       Impact factor: 22.682

5.  Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.

Authors:  Carlos Taxonera; Cristina Rodríguez; Federico Bertoletti; Luís Menchén; Julia Arribas; Mónica Sierra; Lara Arias; Pilar Martínez-Montiel; Alba Juan; Eva Iglesias; Alicia Algaba; Noemí Manceñido; Montserrat Rivero; Manuel Barreiro-de Acosta; Pilar López-Serrano; Federico Argüelles-Arias; Ana Gutierrez; David Busquets; Javier P Gisbert; David Olivares; Marta Calvo; Cristina Alba
Journal:  Inflamm Bowel Dis       Date:  2017-08       Impact factor: 5.325

6.  Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis.

Authors:  Johannan F Brandse; Ron A Mathôt; Desiree van der Kleij; Theo Rispens; Yaël Ashruf; Jeroen M Jansen; Svend Rietdijk; Mark Löwenberg; Cyriel Y Ponsioen; Sharat Singh; Gijs R van den Brink; Geert R D'Haens
Journal:  Clin Gastroenterol Hepatol       Date:  2015-11-09       Impact factor: 11.382

7.  Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.

Authors:  Marta Maia Bosca-Watts; Xavier Cortes; Marisa Iborra; Jose Maria Huguet; Laura Sempere; Gloria Garcia; Rafa Gil; MariFe Garcia; Marga Muñoz; Pedro Almela; Nuria Maroto; Jose Maria Paredes
Journal:  World J Gastroenterol       Date:  2016-12-21       Impact factor: 5.742

Review 8.  An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis.

Authors:  Paweł Kawalec; Andrzej Pilc
Journal:  Arch Med Sci       Date:  2016-03-22       Impact factor: 3.318

9.  Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.

Authors:  Omoniyi J Adedokun; Zhenhua Xu; Colleen W Marano; Richard Strauss; Hongyan Zhang; Jewel Johanns; Honghui Zhou; Hugh M Davis; Walter Reinisch; Brian G Feagan; Paul Rutgeerts; William J Sandborn
Journal:  J Crohns Colitis       Date:  2016-07-20       Impact factor: 9.071

10.  Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres.

Authors:  Mark A Samaan; Polychronis Pavlidis; Jonathan Digby-Bell; Emma L Johnston; Angad Dhillon; Ramesh Paramsothy; Abisoye O Akintimehin; Lucy Medcalf; Guy Chung-Faye; Patrick DuBois; Ioannis Koumoutsos; Nick Powell; Simon H C Anderson; Jeremy Sanderson; Bu' Hussain Hayee; Peter M Irving
Journal:  Frontline Gastroenterol       Date:  2017-10-11
  10 in total
  3 in total

Review 1.  Treatment of Inflammatory Bowel Disease: A Comprehensive Review.

Authors:  Zhaobei Cai; Shu Wang; Jiannan Li
Journal:  Front Med (Lausanne)       Date:  2021-12-20

2.  UK National Survey of Gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease.

Authors:  Gaurav B Nigam; Shadab Nayeemuddin; Evangelos Kontopantelis; Bu'Hussain Hayee; Jimmy K Limdi
Journal:  Frontline Gastroenterol       Date:  2020-01-24

3.  First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus.

Authors:  Maryam Alkhatry; Ahmad Al-Rifai; Vito Annese; Filippos Georgopoulos; Ahmad N Jazzar; Ahmed M Khassouan; Zaher Koutoubi; Rahul Nathwani; Mazen S Taha; Jimmy K Limdi
Journal:  World J Gastroenterol       Date:  2020-11-21       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.